Srihari Gopal

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Venues

Neuropsychiatric disease and treatment

Patient preference and adherence

CNS drugs

Molecular psychiatry

Janssen Research and Development

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Janssen Research and Development

United States

Senior Director :: Neuroscience

Publications

Cesar Giron-Hernandez, Joong Hee Han, Roberta Alberio, Arun Singh, Maria Paz García-Portilla, Maurizio Pompili, R Karl Knight, Ute Richarz, Srihari Gopal, José Antunes
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study. Neuropsychiatric disease and treatment 19 (2023)
Ruth Milz, Carmela Benson, Karl Knight, José Antunes, Dean M Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal, John M Kane
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric disease and treatment 19 (2023)
Ruth Milz, Carmela Benson, Karl Knight, José Antunes, Dean M Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal, John M Kane
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric disease and treatment 19 (2023)
Qingqin S Li, Andrey A Shabalin, Emily DiBlasi, Srihari Gopal, Carla M Canuso, null null, Aarno Palotie, Wayne C Drevets, Anna R Docherty, Hilary Coon
Genome-wide association study meta-analysis of suicide death and suicidal behavior. Molecular psychiatry (2022)
Ibrahim Turkoz, Mehmet Daskiran, H Lynn Starr, Dean M Najarian, Oliver Lopena, Camilo Obando, Alexander Keenan, Carmela Benson, Srihari Gopal
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric disease and treatment 18 (2022)
Amy O'Donnell, Sanjai Rao, Ibrahim Turkoz, Srihari Gopal, Edward Kim
Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate. Neuropsychiatric disease and treatment 17 (2021)
Christoph U Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal, Maju Mathews, Raja Venkatasubramanian, Stephen R Saklad
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS drugs 35 (1) (2021)
Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, Annabelle Godet, Katalin Pungor, Srihari Gopal
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient preference and adherence 15 (2021)
Maju Mathews, Srihari Gopal, Arun Singh, Isaac Nuamah, Katalin Pungor, Wilson Tan, Bernardo Soares, Edward Kim, Adam J Savitz
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies. Neuropsychiatric disease and treatment 16 (2020)
Clifton Blackwood, Panna Sanga, Isaac Nuamah, Alexander Keenan, Arun Singh, Maju Mathews, Srihari Gopal
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire. Patient preference and adherence 14 (2020)
Martin Lambert, Pedro M Sanchez, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia. Neuropsychiatric disease and treatment 16 (2020)
Srihari Gopal, Jagadish Gogate, Katalin Pungor, Edward Kim, Arun Singh, Maju Mathews
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study. Neuropsychiatric disease and treatment 16 (2020)

Srihari Gopal

Publication Activity (10 Years)

Top Topics

Top Venues